Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Anthropic gears up for Wall Street debut: Five things investors need to know
Anthropic is preparing for a potential major Wall Street debut, fueled by rapid growth in AI coding through Claude Code. However, massive cash requirements, heavy